Health Canada approved the first generic version of the diabetes medication Ozempic, produced by Dr Reddy's Laboratories, on April 28, 2026 [2].
The decision marks a significant shift in the accessibility of GLP-1 receptor agonists. As generic alternatives enter the market, the move is expected to challenge the international revenue streams of Novo Nordisk, the original developer of semaglutide [3].
The approval comes amid a period of intense competition within the GLP-1 drug class. These medications, used for treating type 2 diabetes and obesity, have seen a surge in global demand. The entry of a generic competitor in the Canadian market serves as a primary indicator of how Novo Nordisk may fare against lower-cost alternatives in other jurisdictions [3].
Cost reductions associated with generic entries are often substantial. According to one study, generic Ozempic could cost less than $3 per month [1]. This price point represents a drastic decrease from the cost of the brand-name version, potentially expanding patient access across the country.
Dr Reddy's Laboratories is the first company to secure this specific approval from the Canadian regulator. The company's entry into the market coincides with a broader trend of pharmaceutical firms seeking to capture shares of the weight-loss, and diabetes treatment sector [1].
Market analysts said that the Canadian experience will act as a test case for the pharmaceutical industry. The outcome will likely influence how Novo Nordisk manages its pricing and patent strategies globally as more countries consider generic semaglutide options [3].
“Health Canada approved the first generic version of the diabetes medication Ozempic”
The approval of generic semaglutide in Canada signals the beginning of the end for Novo Nordisk's exclusive control over the Ozempic brand in certain markets. By lowering the financial barrier to GLP-1 drugs, this move could increase public health outcomes for diabetes and obesity management while forcing the original manufacturer to innovate or lower prices to maintain market share.
